mk-6913
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2009 (NCT01015677)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Estrogen receptorAGONIST
Estrogen receptor agonist
A Phase Iia was ended prematurerly, development of compound for hot flushes discontinued in 2010 (http://karobio.com/investormedia/pressreleaser/pressrelease?pid=545341)
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)(C)n1nnc2c3c(ccc21)C1=CC(=O)CC[C@@]1(CCOc1ccccc1)C3- Mol. weight
- 401.51 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545274 ↗
Also known as
- mk-6913
- mk-6913
- mk-6913
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01015677 | Phase 2 | Dec 1, 2009 | Merck |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 1 | 1 | 1 | 2009 |
1 organizations
Page 1 / 1